Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Post by kuridogon Nov 26, 2013 11:03pm

172 Views

Post# 21944721

somethin's gotta give...

Material transfer agreement with VitamFero, a member of Genopole, for testing of our biological preservation technology in combination with its live attenuated animal vaccines;
Letter of intent with Biogalenys to develop preclinical data supporting multiple applications of Sirona Biochem's glycoprotein (cell preservation technology);
Letter of intent with Cincinnati Children's Hospital Medical Center, the No. 3 ranked hospital among all honour roll hospitals in the United States. The goal of our collaboration is to combine our proprietary technologies to create a novel skin care technology which will be commercialized by a global leader in cosmetic or consumer packaged goods sales;
Letter of intent with Wanbang Pharma, China's No. 1 ranked anti-diabetic company. Wanbang Pharma will receive an exclusive licence for sales of Sirona Biochem's SGLT2 Inhibitor in China in return for licensing and clinical milestone fees and ongoing royalty payments. Wanbang Pharma will be responsible for financing all clinical studies and development of the SGLT2 inhibitor and Sirona Biochem will receive all of the data generated by Wanbang Pharma with the goal of exponentially raising the value of Sirona Biochem's SGLT2 inhibitor for licensing agreements throughout the rest of the world;
Letter of intent with Obagi Medical Products for a global exclusive licence of Sirona Biochem's skin lightening compound TFC-849. Obagi Medical Products will be responsible for all development, manufacturing and sales of the compound and in return Sirona Biochem will receive licensing and milestone fees and royalty payments;
Letter of intent to create a joint venture with Bloom Burton and Co., Canada's largest and most active health care-specialized investment banking group. The goal of this joint venture is to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.